APC and Sepsis: Initial clinical results indicated that human recombinant APC (hrAPC, drotrecogin alfa (Xigris), Eli Lilly, Indianapolis, IN, USA) reduced mortality in sepsis [12–14], including in patients with severe sepsis and septic shock.